Overview of Koridol

Property	Description
Active ingredient	Tramadol Hydrochloride
Form	Tablets, Capsules, Oral Solution, Injection Solution
Pharmacological class	Opioid analgesic / Centrally acting analgesic
Common use	Relief of moderate to moderately severe pain
Origin	Synthetic compound

What Type of Medicine is Koridol?

Koridol is a pharmaceutical preparation whose active ingredient is Tramadol Hydrochloride, a centrally acting synthetic opioid analgesic. It functions to manage pain by acting directly on the central nervous system.

This medication is an Rx-only product, designating its need for prescription status. As a synthetic compound, Koridol is chemically manufactured and is not derived directly from natural opium alkaloids. Its primary classification as an opioid analgesic stems from its effects on specific receptors in the brain. The drug is intended to relieve pain that falls into the categories of moderate to moderately severe intensity.

Composition and General Purpose

The core component of Koridol is Tramadol Hydrochloride, which provides relief through a dual mechanism of action. The drug tackles pain through two distinct routes—targeting both the opioid system and pain-regulating chemicals.

The general purpose of Koridol is to provide effective pain relief by employing this multimodal mechanism, which works by both modifying the perception of pain and enhancing the body's natural inhibitory pain signals. The formulation may contain Tramadol Hydrochloride as a single active ingredient product, or it may be available as a combination product in fixed-dose formulations, such as those that include paracetamol.

Available Forms and Product Variations

Koridol is available in several pharmaceutical forms designed to accommodate different therapeutic needs and patient administration routes, including traditional tablets, capsules, and a sterile solution for injection (parenteral administration).

The oral dosage form is the most common and includes both Immediate-release (IR) tablets and Extended-release (ER) tablets or capsules. The Extended-release forms are specifically engineered for sustained action over a longer duration, ensuring continuous pain management, while Immediate-release forms are intended for use when a faster onset of relief is required.

Regulatory References

Tramadol: MedlinePlus Drug Information

What side effects are possible with Koridol?

Possible Side Effects and Safety Information

Koridol (Tramadol Hydrochloride) is an opioid analgesic subject to serious safety warnings, primarily concerning the risks of Addiction, Abuse, and Misuse, which can lead to overdose and death. The drug carries a Boxed Warning—the most serious warning required by the FDA—that also addresses the risks of Life-Threatening Respiratory Depression and Neonatal Opioid Withdrawal Syndrome in infants exposed during pregnancy.

Common and Serious Adverse Reactions

The most common adverse effects (incidence ge 15.0% in clinical trials) are typically related to the nervous and gastrointestinal systems, including dizziness/vertigo, nausea, constipation, headache, and somnolence. These reactions often occur during the initial phase of treatment.

Serious adverse reactions documented in regulatory sources include:

Serotonin Syndrome (potentially life-threatening)
Seizures (risk increases with higher doses or concomitant use of certain drugs)
Adrenal insufficiency
Severe hypotension/syncope

Safety Restrictions and Populations

Koridol is contraindicated in children younger than 12 years of age and in adolescents younger than 18 years following tonsillectomy or adenoidectomy due to the risk of life-threatening respiratory depression. Use in adolescents aged 12 to 18 with specific risk factors for respiratory depression should be avoided.

Caution is advised in older patients, who may be more susceptible to common side effects and may require a lower maximum daily dose. Dosage adjustments are also necessary for patients with severe renal impairment. Concomitant use with benzodiazepines or other Central Nervous System depressants is a major safety concern, as it increases the risk of profound sedation, respiratory depression, coma, and death.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Koridol (Tramadol Hydrochloride) is officially classified as an acute, potentially life-threatening event requiring immediate intervention. Regulatory documents state that documented clinical manifestations primarily involve Central Nervous System (CNS) depression, presenting as symptoms ranging from somnolence and stupor to profound coma. The most critical, potentially fatal outcome is respiratory depression. Other officially listed manifestations include tonic-clonic seizures, miosis, and cardiovascular effects such as hypotension. A severe, documented complication is the potential for Serotonin Syndrome, often associated with CNS findings.

All regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted for severe symptoms, especially respiratory distress or unresponsiveness. The documented intervention for reversing opioid-related respiratory depression is Naloxone; however, official labeling notes that its use must be managed cautiously as it carries the risk of precipitating seizures. Management officially consists of symptomatic and supportive treatment, with continuous monitoring of the patient's CNS and respiratory status. Regulations also note that elderly or debilitated patients face an increased risk of severe respiratory depression.

Therapeutic Uses of Koridol

What Koridol Treats: Main Uses and Benefits

Koridol is a medication commonly applied to provide symptomatic support in situations involving pronounced discomfort, generally relevant for moderate to moderately severe pain. It is used to relieve moderate to moderately severe pain, including pain after surgery, particularly when other pain medicines have not provided sufficient relief or cannot be tolerated. It is commonly used when symptoms cluster into patterns requiring additional symptomatic support, generally falling within the scope of symptoms that interfere with daily functioning.

Management of Moderate to Moderately Severe Pain

This domain focuses on providing support that helps ease the overall symptom burden when symptoms are not adequately managed by first-line pain management options. Koridol is relevant across domains involving significant symptom expression, including musculoskeletal and post-operative contexts, assisting with maintaining functional stability during symptomatic periods. The medication is commonly used across conditions involving episodic or fluctuating manifestations, providing supportive relief for symptoms associated with acute episodes, chronic symptom patterns, and specialized discomfort such as neuropathic components.

Quick Fact: Support for Pronounced Symptoms

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Koridol (Tramadol Hydrochloride)

Official regulatory guidelines strictly define the population groups eligible to use Koridol. The medicine is primarily approved for adults aged 18 years and older under standard labeled conditions.

Absolute Contraindications (Must Not Use)

Koridol is contraindicated for several populations due to safety concerns documented in labeling:

Children under 12 years of age.
Adolescents under 18 years following tonsillectomy or adenoidectomy.
Patients with acute or severe bronchial asthma or significant respiratory depression.
Individuals with acute intoxication from alcohol, hypnotics, opioids, or psychotropic medicinal products.
Patients taking or having recently taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Populations Requiring Conditional or Restricted Use

Use is not recommended for patients with severe hepatic impairment or severe renal impairment (Creatinine Clearance less than 30 mL/min).

Caution is required for patients over 75 years of age and for those with a history of seizures or increased intracranial pressure.

Pregnancy and Lactation Status

The medicine is not generally recommended during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome with prolonged use. Use is also not recommended for nursing mothers due to the risk of serious adverse reactions in the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formally Contraindicated and Restricted Combinations

The regulatory label states that co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated and requires a mandatory 14-day separation period after therapy discontinuation. The product is also restricted for use in cases of acute intoxication with other Central Nervous System (CNS) depressants, including alcohol, narcotics, hypnotics, or psychotropic medications. Use with alcohol or alcohol-containing beverages must be restricted due to the enhanced risk of profound sedation and respiratory depression.

Interactions Affecting Drug Exposure

The drug's interaction profile is significantly influenced by metabolism involving CYP2D6 and CYP3A4 enzymes. Inhibitors of the CYP2D6 enzyme (e.g., fluoxetine, quinidine) are documented to increase the parent drug's plasma concentration while decreasing the exposure of the active M1 metabolite. Conversely, CYP3A4 Inducers (such as Carbamazepine and St. John's Wort) accelerate metabolism, resulting in a reduced analgesic effect, and co-administration with Carbamazepine is explicitly not recommended.

Additive Pharmacodynamic Effects

Combining the product with other Serotonergic Drugs (including SSRIs, SNRIs, and Triptans) is linked to an enhanced risk of developing Serotonin Syndrome and seizures due to additive serotonergic activity. Co-administration with other CNS Depressants (e.g., benzodiazepines, other opioids) is documented to increase the risk of profound sedation and respiratory depression. The regulatory documents also note that CYP2D6 Ultra-Rapid Metabolizers face a heightened risk of interaction severity due to rapid metabolic conversion.

Mechanism of Action

How Koridol Works: Mechanism of Action

Koridol modulates neural signaling primarily within the central nervous system through receptor and ion channel mechanisms. The drug functions as a selective agonist for the Kappa Opioid Receptor ( KOR), a G-protein coupled receptor ( GPCR). Activation of the KOR initiates an inhibitory cascade, engaging the G i/ o protein pathway.

This cascade suppresses neuronal excitability by two main processes: triggering the opening of potassium channels (causing potassium efflux and hyperpolarization), and inhibiting voltage-gated calcium channels. The resulting reduced calcium influx into the presynaptic terminal limits the subsequent release of various neurotransmitters, including dopamine.

This targeted inhibition of signaling—particularly within the mesolimbic system and nociceptive pathways—contributes to a reduction in the transmission of nociceptive stimuli and modulates affective circuits, which can include shifts toward dysphoria.

The mechanism focuses solely on pharmacodynamic modulation of key receptor systems and the resultant biochemical signaling events.

Dosage and Administration Information

How to Use Koridol: Administration Guidelines

Koridol (Tramadol Hydrochloride) is an analgesic administered via several approved methods, with specific dosing regimens defined by its formulation.

Administration Scope

Feature	Guideline
Route of administration	The approved routes include Oral (PO), Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC) injection, depending on the product form.
Dosing schedule (Adults)	Immediate-Release (IR): Typically 50 mg to 100 mg, taken every 4 to 6 hours. The maximum daily dose is strictly limited to 400 mg. Extended-Release (ER): Usually initiated at 100 mg once daily, with a maximum daily dose of 300 mg.
Timing in relation to meals	The medication can be taken with or without food. For Extended-Release forms, standard practice involves maintaining a consistent intake pattern (e.g., always with food).

Procedural and Population Rules

Procedural Condition	Guideline
Special handling	Extended-Release forms must be swallowed whole and must not be crushed, chewed, split, or dissolved to preserve the release mechanism. Intravenous injection must be administered slowly.
Population rules	Older adults (over 75 years): The maximum IR daily dose may be reduced to 300 mg. Severe Renal/Hepatic Impairment: The dosing interval for IR forms must be extended, and ER forms are generally not recommended.

Use Protocol

Usage typically follows the principle that Koridol is intended for the shortest duration necessary for relief. If long-term use is established, regular monitoring is required to reassess the continued need for the medicine. Upon discontinuation, especially after extended use, the dosage must be tapered gradually.

Recent Clinical Evidence

Research Evidence and Overview of Studies for Koridol

This section offers an overview of the official research structure and findings for Koridol (Tramadol), focusing on the types of clinical studies that have been conducted and the limitations identified by scientific bodies. This information is purely descriptive and does not constitute medical advice or treatment instruction.

Evidence for Acute Moderate to Moderately Severe Pain

Research has examined Koridol in short-term Randomized Controlled Trials (RCTs) where patients experienced pain that occurs suddenly, such as after a surgical procedure or due to an acute injury. These studies explored how symptoms change over time in the hours or days following an acute event, primarily by measuring pain intensity scores. Findings describe patterns where measurable changes in pain scores were reported when comparing the drug's outcomes to those observed with a placebo. However, the follow-up durations were limited, and these studies offer limited information for long-term outcomes or sustained functional recovery.

Evidence for Chronic Moderate to Moderately Severe Pain

The evidence base for Koridol was studied for managing persistent pain by synthesizing findings from multiple trials through systematic reviews and meta-analyses. This research explored its use in conditions marked by functional limitations, such as chronic low back pain and osteoarthritis. Studies mainly examined outcomes reflecting daily functioning and changes in average pain scores over several weeks.

Studies report how symptoms evolved in the observed populations, but the results have been mixed. Comprehensive reviews have indicated that the average reduction in pain scores reported in these trials may not reach the level considered a minimal clinically important difference (MCID) for many patients. Overall, the certainty remains low for observed changes being sustained in many chronic pain contexts.

Evidence in Special Patient Groups

Koridol was evaluated in specific populations, including older adults and patients with renal or hepatic impairment, through studies that focused on pharmacokinetic profiles. These findings help regulatory bodies establish specific dosage adjustment recommendations. However, this research does not determine whether an individual will respond similarly in terms of symptom changes compared to the broader adult population. Evidence for its use in pediatric patients is highly constrained.

Frequently Asked Questions (FAQ)

Common questions about Koridol (FAQ)

Q: Does Koridol have a generic name?

The active ingredient in Koridol is Tramadol Hydrochloride. Official documents and nomenclature sections identify this compound as the generic name for the medicine.

Q: How quickly does Koridol start working?

Clinical data indicates that for the immediate-release form, relief may typically begin within about one hour of administration. The exact timing and speed of effect can vary individually.

Q: What happens if I miss a dose of Koridol?

Regulatory patient instructions state that a missed dose should be skipped entirely, and the next dose should be taken at its regularly scheduled time. Official guidance advises against taking a double dose to make up for the missed one.

Q: Is it possible to be allergic to Koridol?

Yes, the medicine is formally contraindicated in individuals with a known allergy or suspected hypersensitivity to the active ingredient or any other opioid. Official sources emphasize this restriction for patient safety.

Q: What should I do if I feel dizzy after taking Koridol?

Dizziness is a commonly reported side effect, especially when starting the medicine. Regulatory patient guidance indicates that sitting up or standing slowly may help minimize dizzy spells. Warnings advises against driving or operating machinery until the medicine's full effect on alertness is known.

Q: Can Koridol interact with supplements like vitamins?

Official drug labeling notes that substances affecting the CYP2D6 liver enzyme could alter the drug’s effectiveness. This includes certain supplements. It is necessary to inform a healthcare provider about all supplements and other substances being taken.

Q: Do I need to get blood tests while taking Koridol?

Official guidance does not mandate routine blood tests for all users. However, since the medicine is processed by the liver and kidneys, close monitoring and potential dose adjustment are required for patients with severe impairment in these organs.

Q: How long do the effects of Koridol last?

The pain-reducing effects of the immediate-release formulation are noted in regulatory information to typically last approximately six hours. This duration can vary.

Q: Can Koridol be taken with blood pressure medicine?

The medicine carries a warning regarding the risk of severe low blood pressure (hypotension) that can lead to fainting. Therefore, caution is advised when it is taken alongside other medications that can also compromise blood pressure.

Q: Where can I find the patient leaflet for Koridol?

The patient information leaflet, also known as the Medication Guide or Consumer Medicines Information (CMI), is provided by the pharmacist when the prescription is filled. You can also find this regulatory document on official government drug information websites.

Q: If I have a history of heart problems, can I use Koridol?

The medicine can cause severe low blood pressure (hypotension), and use is generally avoided in patients who are in circulatory shock. For other heart-related conditions, caution is necessary, as official warnings note the risk of severe hypotension.

Q: Are there warnings about driving or operating machinery while taking Koridol?

Yes. Official warnings indicate that driving or operating heavy machinery should be avoided. This is because the medicine may cause effects like drowsiness that impair the ability to safely perform these tasks.

Q: Does Koridol interact with common over-the-counter cold medicines?

The official label warns against combining the medicine with other serotonergic drugs, which includes some ingredients found in common over-the-counter cold remedies. Combining them increases the risk of severe side effects like Serotonin Syndrome and respiratory depression.

Q: What happens if Koridol stops working for me?

Regulatory documents recognize that the drug's effectiveness can decrease over time (tolerance). Official warnings advise against increasing the dose without professional consultation. Seeking professional guidance is recommended if tolerance or reduced effectiveness is suspected.

Q: What is Koridol's safety classification in the US/Europe?

The active ingredient is classified as a Schedule IV controlled substance in the United States. This designation means it has recognized medical use but carries a potential for abuse, leading to specific regulatory requirements.

Q: Is Koridol a controlled substance?

Yes, the active ingredient in Koridol is designated as a Schedule IV controlled substance by US regulatory agencies.

Q: Why do some people stop taking Koridol?

Common reasons for discontinuation noted in regulatory materials include the development of common side effects, such as nausea or dizziness. Serious concerns like the potential for addiction, dependence, and reduced effectiveness over time (tolerance) are also significant factors.

Q: Is Koridol a long-term or short-term medicine?

Regulatory documents indicate the medicine should be used for the shortest duration necessary for pain relief. If long-term use is required, official guidance requires a doctor to regularly re-assess the need for the medicine due to the substantial risks associated with extended opioid use.

Q: Does Koridol affect the liver or kidneys?

The active ingredient is processed by the liver and eliminated through the kidneys. Because of this, patients with severe impairment in these organs often require a lower dose or a longer time between doses, as detailed in the official prescribing information.

Q: Are there foods or drinks I need to avoid while on Koridol?

The most significant warning in the regulatory documentation regarding consumption is to avoid or minimize the use of alcohol. The official label does not mandate the avoidance of specific foods or non-alcoholic beverages.

Q: Does Koridol require a special prescription?

Yes, as the active ingredient is a Schedule IV controlled substance, it is subject to special regulatory requirements. This includes specific rules regarding prescription validity and limitations on refills.

Q: Is it normal to feel [Specific mild side effect] after starting Koridol?

Official safety data shows that certain side effects, such as dizziness, nausea, constipation, and drowsiness (somnolence), are very common, occurring in ge 10% of patients in clinical trials. These often occur during the initial phase of treatment.

Q: What is a 'contraindication' for Koridol?

A contraindication is a specific condition or circumstance where official regulatory bodies state the drug must not be used because the risk is too high. Examples for this medicine include severe asthma, certain types of gastrointestinal obstruction, and a history of allergy to the drug.

Q: Are there any known long-term side effects of taking Koridol for years?

Long-term use over many years carries documented risks, including the development of tolerance, physical dependence, addiction, and potential hormonal side effects like androgen deficiency. Official warnings state that periodic medical re-assessment is required for anyone on continued therapy.

Q: Is there a maximum time Koridol can be used?

Official prescribing information does not set a fixed maximum time limit for use. However, it requires that the medicine be used for the shortest duration necessary, with a doctor needing to regularly re-evaluate the need for continued treatment.

Q: Can Koridol make existing conditions worse?

Yes, the official label lists pre-existing conditions that are contraindicated or require great caution because the medicine can worsen them. These include severe respiratory problems, certain gastrointestinal obstructions, and conditions that increase the risk of seizures.

How should Koridol be stored and disposed of?

Official Storage and Disposal Requirements

Koridol (Tramadol Hydrochloride) must be stored and handled strictly according to the conditions detailed in the official regulatory labeling.

Storage Conditions

Requirement	Specification
Temperature	Store at Controlled Room Temperature, 20 to 25 C ( 68 to 77 F).
Protection	Protect from both light and moisture.
Container Rule	Keep the medication in the original container and oral forms tightly closed.
Child Safety	Mandatory to store the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Koridol should be disposed of via an authorized drug take-back program. If a program is unavailable, official guidelines mandate mixing the medicine with an unappealing substance, such as dirt or used coffee grounds, and placing the mixture in a sealed container before disposal in household trash. Unused injection solution portions must be discarded immediately after use, and the product should not be disposed of via wastewater.

Koridol